ClinicalTrials.gg
CompletedNCT06491563Updated Oct 21, 2026

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

A Phase 2 interventional study of BRII-179 and BRII-835 (VIR-2218) in For Treatment of Chronic Hepatitis B Virus Infection, sponsored by Brii Biosciences Limited. Completed at 12 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
125th of 274
150 · median 120
Started
2024
with 33 others
Phase 2
72 of 378
15 open now
Registered
292nd of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 125th largest by enrollment of the 274 interventional ones that give a count, is one of 34 that started in 2024, is one of 72 in phase 2, and was the 292nd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

03

Conditions studied

  • For Treatment of Chronic Hepatitis B Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female aged 18-60 years.
  • 2. ≥ 18 kg/m2 and ≤ 32 kg/m2.
  • 3. Chronic infection for ≥ 6 months.
  • 4. On NRTI therapy for ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • 1. Any chronic or acute medical condition that makes the participant unsuitable for participation.
  • 2. Significant liver fibrosis or cirrhosis.
  • 3. History or evidence of drug or alcohol abuse.
  • 4. History of intolerance to SC or IM injection.
  • 5. History of chronic liver disease from any cause other than chronic infection.
  • 6. History of hepatic decompensation.
  • 7. to the use of PEG-IFNα.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα

    Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy.

    Biological: BRII-179 · Drug: BRII-835 (VIR-2218) · Biological: PEG-IFNα

  • Experimental
    BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα

    Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy.

    Biological: BRII-179 · Drug: BRII-835 (VIR-2218) · Biological: PEG-IFNα

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint

    Time frame: 24 weeks post end of treatment

Secondary outcomes

  1. Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint (in participants with lower baseline HBsAg levels)

    Time frame: 24 weeks post end of treatment

  2. Percentage of participants with treatment-emergent adverse events (TEAEs)

    Time frame: End of Study

  3. Percentage of participants with serious adverse events (SAEs)

    Time frame: End of Study

  4. Clinical assessments including laboratory measurements

    Time frame: End of Study

  5. Appearance of anti-HBs at any timepoint

    Time frame: End of Study

  6. Titers of anti-HBs at any timepoint

    Time frame: End of Study

07

Study locations

12 sites
  • Investigative Site 86004
    Beijing, Beijing Municipality 100000, China
  • Investigative Site 86009
    Beijing, Beijing Municipality 100000, China
  • Investigative Site 86015
    Xiamen, Fujian 361000, China
  • Investigative Site 86012
    Foshan, Guangdong 528000, China
  • Investigative Site 86001
    Guangzhou, Guangdong 510000, China
  • Investigative Site 86013
    Guangzhou, Guangdong 510000, China
  • Investigative Site 86002
    Shenzhen, Guangdong 518000, China
  • Investigative Site 86003
    Shanghai, Shanghai Municipality 200000, China
  • Investigative Site 86008
    Shanghai, Shanghai Municipality 200000, China
  • Investigative Site 86007
    Chengdu, Sichuan 610000, China
  • Investigative Site 86011
    Chengdu, Sichuan 610000, China
  • Investigative Site 86005
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2026, 23 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 23 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2026 → Aug 2026 and completion Jun 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 9, 2024
StartActual
Aug 6, 2024
Primary completionActual
Aug 5, 2026was Dec 2026
CompletionActual
Aug 5, 2026was Jun 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 China)
  • Investigative Site 86004 · Beijing, China
  • Investigative Site 86009 · Beijing, China
  • Investigative Site 86003 · Shanghai, China
  • Investigative Site 86008 · Shanghai, China
Show 4 removed
  • Investigative Site 86004 · Beijing, China
  • Investigative Site 86009 · Beijing, China
  • Investigative Site 86003 · Shanghai, China
  • Investigative Site 86008 · Shanghai, China
Oct 21, 2026
Primary completion
Dec 2026→Aug 5, 2026 (actual)
Oct 21, 2026
Study completion
Jun 2027→Aug 5, 2026 (actual)
Oct 21, 2026
Secondary outcomes
1 edited, 4 time frame changed
What changed in the outcomes
  • ChangedBefore Percentage of participants with abnormalities in hematology, chemistry, and/or coagulation parametersNow Clinical assessments including laboratory measurementsTime frame: 24 weeks post NRTI discontinuation → End of Study
  • Time framePercentage of participants with treatment-emergent adverse events (TEAEs)24 weeks post NRTI discontinuation → End of Study
  • Time framePercentage of participants with serious adverse events (SAEs)24 weeks post NRTI discontinuation → End of Study
  • Time frameAppearance of anti-HBs at any timepoint24 weeks post NRTI discontinuation → End of Study
  • Time frameTiters of anti-HBs at any timepoint24 weeks post NRTI discontinuation → End of Study
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    4 sites added, 4 sites removed
    Show 4 added (4 China)
    • Investigative Site 86004 · Beijing, China
    • Investigative Site 86009 · Beijing, China
    • Investigative Site 86003 · Shanghai, China
    • Investigative Site 86008 · Shanghai, China
    Show 4 removed
    • Investigative Site 86004 · Beijing, China
    • Investigative Site 86009 · Beijing, China
    • Investigative Site 86003 · Shanghai, China
    • Investigative Site 86008 · Shanghai, China
    Primary completion Dec 2026→Aug 5, 2026 (now actual)
    Study completion Jun 2027→Aug 5, 2026 (now actual)
    Secondary outcomes 1 edited, 4 time frame changed
    What changed in the outcomes
    • ChangedBefore Percentage of participants with abnormalities in hematology, chemistry, and/or coagulation parametersNow Clinical assessments including laboratory measurementsTime frame: 24 weeks post NRTI discontinuation → End of Study
    • Time framePercentage of participants with treatment-emergent adverse events (TEAEs)24 weeks post NRTI discontinuation → End of Study
    • Time framePercentage of participants with serious adverse events (SAEs)24 weeks post NRTI discontinuation → End of Study
    • Time frameAppearance of anti-HBs at any timepoint24 weeks post NRTI discontinuation → End of Study
    • Time frameTiters of anti-HBs at any timepoint24 weeks post NRTI discontinuation → End of Study
    + 4 other changes: verification date, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06491563
Lead sponsor
Brii Biosciences Limited
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Aug 6, 2024
Primary completion
Aug 5, 2026
Completion
Aug 5, 2026
Last update
Oct 21, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion